The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE), which is based on the company's proprietary tumor targeting technology known as the nab® platform.

The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab® platform.

The Company's portfolio includes the world's first and only protein-bound chemotherapeutic compound (ABRAXANE®), which is based on the Company's proprietary tumor targeting technology known as the nab ™ platform.